Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2020 | 1 |
2022 | 1 |
2024 | 2 |
Search Results
4 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Current treatment landscape of pancreatic cancer patients in a network of office-based oncologists in Germany.
Future Oncol. 2022 Dec 19. doi: 10.2217/fon-2022-0141. Online ahead of print.
Future Oncol. 2022.
PMID: 36533962
Free article.
ASO Visual Abstract: Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer-The Randomized Multicenter Phase II NEPAFOX Trial.
Goetze TO, Reichart A, Bankstahl US, Pauligk C, Loose M, Kraus TW, Elshafei M, Bechstein WO, Trojan J, Behrend M, Homann N, Venerito M, Bohle W, Varvenne M, Bolling C, Behringer DM, Kratz-Albers K, Siegler GM, Hozaeel W, Al-Batran SE.
Goetze TO, et al. Among authors: kratz albers k.
Ann Surg Oncol. 2024 Apr 4. doi: 10.1245/s10434-024-15145-8. Online ahead of print.
Ann Surg Oncol. 2024.
PMID: 38575722
No abstract available.
Item in Clipboard
Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial.
Goetze TO, Reichart A, Bankstahl US, Pauligk C, Loose M, Kraus TW, Elshafei M, Bechstein WO, Trojan J, Behrend M, Homann N, Venerito M, Bohle W, Varvenne M, Bolling C, Behringer DM, Kratz-Albers K, Siegler GM, Hozaeel W, Al-Batran SE.
Goetze TO, et al. Among authors: kratz albers k.
Ann Surg Oncol. 2024 Mar 8. doi: 10.1245/s10434-024-15011-7. Online ahead of print.
Ann Surg Oncol. 2024.
PMID: 38459418
Item in Clipboard
First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study.
Schliemann C, Gerwing M, Heinzow H, Harrach S, Schwöppe C, Wildgruber M, Hansmeier AA, Angenendt L, Berdel AF, Stalmann U, Berning B, Kratz-Albers K, Middelberg-Bisping K, Wiebe S, Albring J, Wilms C, Hartmann W, Wardelmann E, Krähling T, Heindel W, Gerss J, Bormann E, Schmidt H, Lenz G, Kessler T, Mesters RM, Berdel WE.
Schliemann C, et al. Among authors: kratz albers k.
Cancers (Basel). 2020 Jun 7;12(6):1488. doi: 10.3390/cancers12061488.
Cancers (Basel). 2020.
PMID: 32517329
Free PMC article.
Item in Clipboard
Cite
Cite